3 Reasons to Buy Pfizer Stock
Pfizer is currently pumping out plenty of brand-new approvals this year. The company's latest acquisition should strengthen its oncology business.
Here's Why the Next 4 Months May Be Critical for Pfizer
Pfizer reported record-high revenue in 2022, but the company doesn't yet know what to expect from its coronavirus products in the coming years. Management has said the coronavirus vaccine market ma...
EU regulator backs authorizing Pfizer's vaccine for coronavirus variant XBB.1.5
The European Medicines Agency (EMA) on Wednesday said its human medicines committee (CHMP) recommended authorizing an adapted Comirnaty COVID-19 vaccine targeting the dominant XBB.1.5 variant of Om...
Timeless Titans: 3 Blue-Chip Stocks Destined for 100% Gains by 2024
From early 2022 highs of close to $400, Tesla (NASDAQ: TSLA ) stock plunged to lows of $102 at the beginning of the year. However, the stock is already higher by 120% for year-to-date and trades at...
Pfizer expects to restart production at Rocky Mount plant by Q4
Pfizer Inc said on Friday it expects to restart production at its Rocky Mount manufacturing facility by the fourth quarter of 2023.
EU approves Pfizer's RSV vaccine to protect infants and older adults
The European Commission on Thursday approved Pfizer's vaccine for respiratory syncytial virus (RSV) for use in babies and older adults.
FDA approves Pfizer's RSV vaccine to protect babies from RSV
Pfizer (PFE) receives approval from the FDA on its vaccine for pregnant women to protect infants from RSV. Yahoo Finance Health Reporter Anjalee Khemlani explains the new vaccine and the outlook fo...
FDA greenlights Pfizer's RSV vaccine to protect infants
The U.S. Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants, Pfizer Inc (NYSE:PFE)'s Abrysvo.
Pfizer's (PFE) RSV Vaccine Gets FDA Nod for Pregnant Women
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for the prevention of lower respiratory tract disease in infants through administration to pregnant women.
Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
Returning to the pre-inflation shock level of over $60 means that PFE stock will have to gain more than 65% from here, and we don't think this will materialize anytime
FDA Approves First RSV Vaccine For Kids—Given To Pregnant Moms—Here's What To Know
RSV infects nearly every child by the time they reach 2 and can cause serious, potentially fatal, illness.
Pfizer maternal RSV vaccine gets FDA approval
A Pfizer Inc. PFE, +0.95% vaccine designed to protect babies from respiratory syncytial virus, or RSV, got a green light Monday from the U.S. Food and Drug Administration — a key milestone for infa...
US FDA approves Pfizer's maternal RSV vaccine to protect infants
The U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their b...
FDA approves Pfizer maternal RSV vaccine for infants
Pfizer hopes that its respiratory syncytial virus vaccine will be available to the public by the end of October or the beginning of November.
Related Companies